Navigation Links
Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
Date:1/6/2011

farction, occurred on allopurinol alone.  No serious adverse events or deaths occurred while patients were on RDEA594. Adverse events were infrequent, not dose related and comparable between the groups receiving RDEA594 and placebo.  Five patients discontinued treatment due to an adverse event; three occurred on allopurinol alone and two occurred on the combination of allopurinol and RDEA594.  Preliminary Safety Results of Phase 2b Combination Therapy Study of RDEA594 in Allopurinol-Refractory Gout Patients

Percent of Patients with Treatment-Related Adverse Events Occurring in More Than One Patient Treatment GroupsRDEA594 600mg qd + allopurinol

RDEA594 400mg qd + allopurinol

RDEA594 200mg qd + allopurinol

RDEA594 All Doses + allopurinol

Pooled Placebo + allopurinolNumber of patients

48

42

46

136

72Any Adverse Event

10.4%

9.5%

2.2%

7.4%

13.9%Diarrhea

0%

2.4%

0%

0.7%

2.8%Dyspepsia

2.1%

0%

0%

0.7%

1.4%Dizziness

0%

0%

2.2%

0.7%

2.8%Lipase Increased

0%

2.4%

0%

0.7%

1.4%Hematuria

0%

2.4%

0%

0.7%

2.8%"The encouraging safety and efficacy results from this multi-center, randomized study of RDEA594 in combination with allopurinol provide a strong basis to advance this innovative product into Phase 3 clinical development," commented John S. Sundy, MD, PhD, Associate Professor of Medicine and Director of the Duke Clinical Research Unit at Duke University Medical Center.  "There is a major unmet medical need for a well-tolerated, orally administered urate-lowering therapy that works by a novel mechanism of action and can be given alone or in combination with other agents to the many patients who are not adequately treated with currently available products."

"We are very please
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Ardea Biosciences to Present at Two Upcoming Investor Conferences
2. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
3. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
4. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
7. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
8. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
9. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... EDISON, N.J. , May 6, 2015 Bone ... $2M funding round with Hankey Capital, LLC ("Hankey Capital") of ... developing a proprietary protein for use in bone regenerative medicine ... Nell-1) for use with patients undergoing spinal fusion. ... "We are pleased with the completion of this round of ...
(Date:5/6/2015)... Follow us on LinkedIn ... with diameter ranging between 2 to 10 nanometers, ... materials market. The unique electroluminescent, photoluminescent, photo-physical, and ... confinement effect render the nanoparticles versatile and flexible ... technological, and commercial applications. A host of value-added ...
(Date:5/6/2015)... -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of ... Cassian Yee , M.D., Professor, Department of Melanoma ... of Texas MD Anderson Cancer Center joined its scientific ... Immunology, Division of Cancer Medicine, and Director, Solid Tumor ... University of Texas MD Anderson Cancer Center.  ...
(Date:5/6/2015)... Dr Jaspreet Singh , Senior Research ... a speech at the 2015 Asian Starch Conference, to be ... Center.  , ... topic: ,Potato Starch: A Potential Source for the Creation ... Co-editor of a 528 page text book entitled "Advances ...
Breaking Biology Technology:Bone Biologics Corp Completes Financing With Hankey Capital, LLC 2Bone Biologics Corp Completes Financing With Hankey Capital, LLC 3Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 2Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 3Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2
... Corp. (TSX: HBP / Frankfurt: WKN 918864), ... Corp.,announces that at the Company,s Annual General Meeting ... the resolutions presented by,management, appointing KPMG LLP as ... Kay, Slawomir Majewski, and Gordon Lickrish as,directors, and ...
... Jan. 30 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ... novel anti-infective products, today,announced that it has closed ... warrants, resulting in the receipt of $21 million ... the proceeds from the financing to support,the manufacture ...
... Jan. 30 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... bio-enhanced feed products sold during the fourth,quarter of ... and increased,25% over the same period in the ... ("Kiwa Tianjin") is a joint-venture of Kiwa,and Tianjin ...
Cached Biology Technology:Helix BioPharma shareholders vote in favour of management 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 3Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007 2
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... -- Rice University scientists have unveiled a revolutionary new ... into steam. The new "solar steam" method from Rice,s ... even produce steam from icy cold water. Details ... in ACS Nano . The technology has an ...
... after Hurricane Sandy hit, NJIT Professor Michel Boufadel was awarded ... of the storm on the New Jersey shoreline. The ... a team of eight researchers to the beaches of Raritan ... students is still fanning out over the shoreline and ...
... getting, when they select females for mating, according to a ... Wisconsin-Milwaukee in the US. His work, which is one of ... mating behaviors in a nocturnal anuran (frog or toad), is ... . Animals display a number of courtship behaviors and ...
Cached Biology News:Rice unveils super-efficient solar-energy technology 2Rice unveils super-efficient solar-energy technology 3NJIT civil engineer receives NSF grant to study storm's impact on Jersey Shore 2Vision stimulates courtship calls in the grey tree frog 2
Goat polyclonal to Centaurin alpha 2**...
... background ,This solution greatly enhances antigen-antibody reactions, ... obtained with conventional methods. ,Two kinds of ... antibodies, which can suppress the background and ... versatility ,It is applicable to various assay ...
Monocarboxylate (lactate) transporter 2...
Mouse anti human pro-Relaxin-2...
Biology Products: